ASRT
Price
$11.59
Change
-$0.40 (-3.34%)
Updated
Feb 4, 02:18 PM (EDT)
Capitalization
76.3M
35 days until earnings call
Intraday BUY SELL Signals
VTRS
Price
$14.34
Change
+$0.66 (+4.82%)
Updated
Feb 4, 03:26 PM (EDT)
Capitalization
15.76B
26 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ASRT vs VTRS

Header iconASRT vs VTRS Comparison
Open Charts ASRT vs VTRSBanner chart's image
Assertio Holdings
Price$11.59
Change-$0.40 (-3.34%)
Volume$499
Capitalization76.3M
Viatris
Price$14.34
Change+$0.66 (+4.82%)
Volume$3.58K
Capitalization15.76B
ASRT vs VTRS Comparison Chart in %
ASRT
Daily Signal:
Gain/Loss:
VTRS
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ASRT vs. VTRS commentary
Feb 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ASRT is a Buy and VTRS is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 04, 2026
Stock price -- (ASRT: $11.99 vs. VTRS: $13.68)
Brand notoriety: ASRT and VTRS are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ASRT: 93% vs. VTRS: 105%
Market capitalization -- ASRT: $76.3M vs. VTRS: $15.76B
ASRT [@Pharmaceuticals: Generic] is valued at $76.3M. VTRS’s [@Pharmaceuticals: Generic] market capitalization is $15.76B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $64.79B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.75B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ASRT’s FA Score shows that 0 FA rating(s) are green whileVTRS’s FA Score has 3 green FA rating(s).

  • ASRT’s FA Score: 0 green, 5 red.
  • VTRS’s FA Score: 3 green, 2 red.
According to our system of comparison, VTRS is a better buy in the long-term than ASRT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ASRT’s TA Score shows that 6 TA indicator(s) are bullish while VTRS’s TA Score has 4 bullish TA indicator(s).

  • ASRT’s TA Score: 6 bullish, 5 bearish.
  • VTRS’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, ASRT is a better buy in the short-term than VTRS.

Price Growth

ASRT (@Pharmaceuticals: Generic) experienced а -2.20% price change this week, while VTRS (@Pharmaceuticals: Generic) price change was +4.27% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -1.83%. For the same industry, the average monthly price growth was -2.35%, and the average quarterly price growth was +12.98%.

Reported Earning Dates

ASRT is expected to report earnings on Mar 11, 2026.

VTRS is expected to report earnings on Mar 02, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-1.83% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VTRS($15.8B) has a higher market cap than ASRT($76.3M). ASRT YTD gains are higher at: 32.194 vs. VTRS (9.880). ASRT has higher annual earnings (EBITDA): 4.53M vs. VTRS (-598.9M). VTRS has more cash in the bank: 1.16B vs. ASRT (60M). ASRT has less debt than VTRS: ASRT (39.9M) vs VTRS (14.7B). VTRS has higher revenues than ASRT: VTRS (14.1B) vs ASRT (137M).
ASRTVTRSASRT / VTRS
Capitalization76.3M15.8B0%
EBITDA4.53M-598.9M-1%
Gain YTD32.1949.880326%
P/E RatioN/A236.20-
Revenue137M14.1B1%
Total Cash60M1.16B5%
Total Debt39.9M14.7B0%
FUNDAMENTALS RATINGS
ASRT vs VTRS: Fundamental Ratings
ASRT
VTRS
OUTLOOK RATING
1..100
884
VALUATION
overvalued / fair valued / undervalued
1..100
75
Overvalued
13
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9696
PRICE GROWTH RATING
1..100
436
P/E GROWTH RATING
1..100
991
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VTRS's Valuation (13) in the null industry is somewhat better than the same rating for ASRT (75) in the Pharmaceuticals Major industry. This means that VTRS’s stock grew somewhat faster than ASRT’s over the last 12 months.

VTRS's Profit vs Risk Rating (100) in the null industry is in the same range as ASRT (100) in the Pharmaceuticals Major industry. This means that VTRS’s stock grew similarly to ASRT’s over the last 12 months.

VTRS's SMR Rating (96) in the null industry is in the same range as ASRT (96) in the Pharmaceuticals Major industry. This means that VTRS’s stock grew similarly to ASRT’s over the last 12 months.

VTRS's Price Growth Rating (6) in the null industry is somewhat better than the same rating for ASRT (43) in the Pharmaceuticals Major industry. This means that VTRS’s stock grew somewhat faster than ASRT’s over the last 12 months.

VTRS's P/E Growth Rating (1) in the null industry is significantly better than the same rating for ASRT (99) in the Pharmaceuticals Major industry. This means that VTRS’s stock grew significantly faster than ASRT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ASRTVTRS
RSI
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
59%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
74%
Bearish Trend 2 days ago
62%
Momentum
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
70%
MACD
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
68%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
66%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
63%
Advances
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
71%
Declines
ODDS (%)
Bearish Trend 7 days ago
84%
Bearish Trend 8 days ago
66%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
59%
Aroon
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
70%
View a ticker or compare two or three
Interact to see
Advertisement
ASRT
Daily Signal:
Gain/Loss:
VTRS
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
ZAP31.030.52
+1.70%
Global X U.S. Electrification ETF
ASHR33.240.16
+0.48%
Xtrackers Harvest CSI 300 China A ETF
BESF36.07N/A
N/A
Bastion Energy ETF
BXSY16.14-0.10
-0.62%
Bexil Investment Trust
MAGX54.90-1.89
-3.33%
Roundhill Daily 2X Lon Mag Sev ETF

ASRT and

Correlation & Price change

A.I.dvisor tells us that ASRT and COLL have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ASRT and COLL's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ASRT
1D Price
Change %
ASRT100%
-2.04%
COLL - ASRT
26%
Poorly correlated
+0.85%
INDV - ASRT
26%
Poorly correlated
+1.29%
CPHI - ASRT
25%
Poorly correlated
+1.11%
TKNO - ASRT
24%
Poorly correlated
+2.95%
VTRS - ASRT
24%
Poorly correlated
N/A
More

VTRS and

Correlation & Price change

A.I.dvisor indicates that over the last year, VTRS has been loosely correlated with AMRX. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if VTRS jumps, then AMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VTRS
1D Price
Change %
VTRS100%
N/A
AMRX - VTRS
50%
Loosely correlated
+0.42%
ELAN - VTRS
48%
Loosely correlated
-1.62%
AMPH - VTRS
45%
Loosely correlated
+1.15%
EBS - VTRS
43%
Loosely correlated
-1.45%
ZTS - VTRS
38%
Loosely correlated
-2.02%
More